An Open Label Extension Study of GBT440 Administered Orally to Patients with Sickle Cell Disease Who Have Participated in GBT440 Clinical Trials

Type of Cancer
Unknown

Site
Bethesda

Protocol Number
GBT440-034

To Learn More Call
(201)-510-0950